20190318 PR Natixis loan EN
Category: Press release
NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
20190313 – Neoviva – EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
20181220-Phase-1-TG4001-EN
Transgene Announces Financial Calendar for 2019
20181217 Financial calendar 2019 EN
Transgene Announces Upcoming Investor Meetings
20181205-PR-Investors-Meeting-agenda-T1-2019.pdf
Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
20181112 PR TG0150 Phase 1 data combi AASLD EN
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
20181107 SITC Poster EN
Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
20181107 SITC Joint BioInvent Transgene EN
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
Press Release NEC- Transgene EN